^
Association details:
| Biomarker: | HER-2 G778_P780dup |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Excerpt:
Description of HER2 mutations and clinical outcomes of patients treated with dacomitinib….The activity of dacomitinib in patients with HER2 mutations in this trial confirms the earlier reports of benefit with HER2 kinase inhibitors in similar patients.
DOI:
10.1093/annonc/mdv186
Trial ID:
